HAEMONETICS CORP Form 8-K July 24, 2003

> SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

> > FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): July 24, 2003

HAEMONETICS CORPORATION (Exact Name of Registrant as Specified in its Charter)

Massachusetts	1-10730	04-2882273
(State or other jurisdiction of	(Commission File	(IRS Employer
incorporation or organization)	Number)	Identification Number)

400 Wood Road Braintree, MA (Address of principal executive offices)

02184 -----(Zip Code)

Registrant's telephone number, including area code (781) 848-7100

Item 9. Regulation FD Disclosure.

The following information is intended to be included under "Item 12. Results of Operations and Financial Condition" and is included under this Item 9 in accordance with SEC Release No. 33-8216.

On July 24,2003 Haemonetics Corporation (the "Company") issued a press release regarding its financial results for the quarter ended June 28, 2003. The Company's press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K and the Exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

Exhibits

99.1 Press Release dated July 24, 2003, of Haemonetics Corporation.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HAEMONETICS CORPORATION

Date: July 24, 2003

By: s/Ronald J. Ryan

Ronald J. Ryan, Senior Vice President and Chief Financial Officer

3